- A group of 21 Democratic AGs filed an amicus brief with the U.S. Court of Appeals for the Ninth Circuit supporting Oregon in its defense of H.B. 4005, which requires pharmaceutical manufacturers to report certain information about specific new prescription drugs and historical information about pricing for existing drugs.
- The U.S. District Court for the District of Oregon had granted summary judgment in favor of Pharmaceutical Research and Manufacturers Association—a trade association of U.S. drug manufacturers—on its First Amendment claim, and Oregon appealed.
- In the brief, the AGs argue that drug transparency laws like H.B. 4005 are important in states’ efforts to lower costs of prescription drugs.
- The AGs ask the Ninth Circuit to reverse the district court’s grant of summary judgment.